BCL11A and Schnyder corneal dystrophy: This experiment of nature has inspired a therapeutic strategy to reactivate fetal γ-globin via genetic perturbation of the γ-globin repressor BCL11A, resulting in transcriptional reactivation and considerable clinical improvement for SCD patients44,49,57,58.